Merck & Co. Inc. (NYSE: MRK) is rewarding its shareholders once again with a quarterly dividend of $0.81 per share, payable ...

For a more detailed discussion of Aduro's Q3 2025 results, please refer to the Company's condensed interim consolidated financial statements and interim management discussion & analysis for the three ...

Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $200 billion by market cap, the ...

Merck & Co. Inc. closed 41.19% below its 52-week high of $134.63, which the company reached on June 25th.

A class action lawsuit was filed against Merck & Co. (MRK) by Levi & Korsinsky on February 12, 2025. The plaintiffs ...

NUREMBERG, Germany, March 31, 2025 /PRNewswire/ -- SK chemicals is participating in a coatings and painting exhibition for the first time, strengthening marketing efforts for each material.

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data sho ...

Merck (MRK) released phase III data for an injection ... as drugmakers who have pursued similar routes have claimed the drugs are different products if they are administered through an injection ...

Speaking at the firm’s capital markets day meeting on March 25, Shell CEO Wael Sawan said that the chemical business is “not delivering adequate returns” and that “we do not believe we are ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.